Results 211 to 220 of about 45,512 (293)

NRAS NP_002515.1:p.Q61E [PDF]

, 2020
openaire   +1 more source

Immune and cellular determinants of response to HMA‐venetoclax regimens in acute myeloid leukemia

HemaSphere, Volume 10, Issue 10, October 2026.
Abstract Hypomethylating agents (HMAs) combined with Venetoclax have reshaped the therapeutic landscape of acute myeloid leukemia (AML), yet the biological determinants of response remain unclear. We integrated clinical and genomic profiling in 132 newly diagnosed or relapsed/refractory AML patients treated with HMA‐Venetoclax and performed single‐cell
Alfredo Marchetti, Francesca Lazzaroni, Matteo Claudio Da Via', Marta Lionetti, Giulia Maggioni, Alessia Campagna, Denise Ventura, Giorgio A. Croci, Alessio Marella, Akihiro Maeda, Antonio Matera, Emanuele Calvi, Margherita Scopetti, Filippo Viviani, Nicolò Rampi, Davide Bonometti, Elena Benzoni, Manuela Zappa, Sonia Fabris, Marzia Barbieri, Stefania Pioggia, Claudia Leoni, Antony Ricchiuti, Matteo G. D. Porta, Mariarita Sciumè, Francesco Passamonti, Nicola S. Fracchiolla, Niccolò Bolli   +27 more
wiley   +1 more source

<i>NRAS</i> mRNA-Degrading Bifunctional Small Molecules Induce Diverse Cellular Morphological Changes in Cancer Cells. [PDF]

JACS Au
Jiang M, Hösle D, Liu Y, Sievers S, Wu P.   +4 more
europepmc   +1 more source

MEK inhibition achieves robust and durable responses in Erdheim–Chester disease

HemaSphere, Volume 10, Issue 10, October 2026.
Abstract Erdheim–Chester disease (ECD) is a rare histiocytic neoplasm characterized by heterogeneous clinical manifestations and limited evidence to guide targeted therapy. While MEK inhibitors (MEKi) are increasingly used, data on their real‐world efficacy, durability, and safety remain incomplete.
Francesco Pegoraro, Félicien Triboulet, Matthias Papo, Francesco Peyronel, Anita Argentieri, Jerome Razanamahery, Ahmed Idbaih, Polyzois Makras, Ofer Shpilberg, Oshrat Hershkovitz‐Rokah, Michael Girschikofsky, Matthew Collin, Kristian Bowles, Satyen H. Gohil, Rodothea Amerikanou, Emmanuel Ledoult, Tanguy Le Scornet, Mathilde de Menthon, Etienne Riviere, Xavier Boulu, Henry Dupuy, Achille Aouba, Stanislas Faguer, Xavier Solanich, Elena Sieni, Stéphane Barete, Chiara Bellino, Alessandro Tomelleri, Corrado Campochiaro, Lorenzo Dagna, Zahir Amoura, Jean‐François Emile, Fleur Cohen‐Aubart, Augusto Vaglio, Julien Haroche   +34 more
wiley   +1 more source

S-nitrosylation topology in melanoma: established mechanisms, unresolved redox-immune links, and a testable framework. [PDF]

Redox Biol
Srivastava J, Premi S.
europepmc   +1 more source

Real‐World Outcomes of Nivolumab and Ipilimumab in Metastatic Melanoma as Third Line and Beyond

International Journal of Cancer, Volume 159, Issue 7, Page 1780-1787, 1 October 2026.
Progression after anti‐PD‐1‐based therapy is a predominant scenario in metastatic melanoma. However, real‐world data informing treatment of metastatic melanoma in later lines remains scarce. This retrospective nationwide, population‐based cohort study shows in a real‐world setting that nivolumab plus ipilimumab can induce durable responses beyond the ...
Yago Garitaonaindia, Søren Kjær Petersen, Louise M. Guldbrandt, Troels H. Borch, Christina H. Ruhlmann, Rasmus Blechingberg Friis, Adam A. Luczak, Lars Bastholt, Henrik Schmidt, Inge Marie Svane, Eva Ellebaek, Marco Donia   +11 more
wiley   +1 more source

The clinical relevance of RAS pathway gene mutations in childhood B-cell acute lymphoblastic leukemia. [PDF]

Ann Hematol
Chen X, Gao L, Zhang Y, Hu Y, Pan J, Li Z, Lu J, Li Y, Hu S.   +8 more
europepmc   +1 more source

Colorectal Cancer: Epidemiology, Risk Factors, Signaling Pathways, Clinical Features, Screening, Diagnosis, and Management

MedComm, Volume 7, Issue 10, October 2026.
Colorectal cancer is a heterogeneous, adaptive disease shaped by population‐level risk, genomic and epigenetic alterations, tumor ecosystem evolution, and treatment pressure. This review integrates epidemiology, risk factors, signaling networks, clinical presentation, screening, molecular diagnosis, and stage‐ and biomarker‐guided management while ...
Kairui Wan, Ke Tang, Linglong Wang, Qin Tian, Mingwei Zheng, Cheng Qian, Limei Liu   +6 more
wiley   +1 more source

Integrated longitudinal analysis of ctDNA, radiologic response, and tumor volume reveals spatial and temporal heterogeneity in advanced melanoma. [PDF]

J Transl Med
Heidrich I, Streckenbach A, Rautmann C, Freiberg H, Kött J, Geidel G, Rünger A, Zell T, Roeper C, Hansen-Abeck I, Abeck F, Schneider SW, Smit DJ, Pantel K, Gebhardt C.   +14 more
europepmc   +1 more source

Profiling Gut Microbiome and Metabolites Aids Diagnosis and Prediction of Progression in Mild Cognitive Impairment

MedComm, Volume 7, Issue 10, October 2026.
Fecal samples were collected and subjected to high‐throughput metabolomics and microbiome sequencing. Representative markers were identified for distinguishing mild cognitive impairment (MCI) cases from controls and predicting progression of cognitive decline in MCI over a year.
Birong Zhang, Richard Brown, Antony Bayer, Joanna Waring, B. Paul Morgan, Julian R. Marchesi, You Zhou   +6 more
wiley   +1 more source